BMAL1 and systemic lupus erythematosus: In summary, although the absence of Bmal1 in myeloid cells did not dramatically modify murine lupus symptoms during the 6 weeks of treatment, it led to increase anti-dsDNA antibody levels, renal immune complex deposition, and enhanced dermal tissue neutrophil infiltration.